Enter Your Email Address Are you on the lookout for UK growth stocks?If so, get this FREE no-strings report now.While it’s available: you’ll discover what we think is a top growth stock for the decade ahead.And the performance of this company really is stunning.In 2019, it returned £150million to shareholders through buybacks and dividends.We believe its financial position is about as solid as anything we’ve seen.Since 2016, annual revenues increased 31%In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259Operating cash flow is up 47%. (Even its operating margins are rising every year!)Quite simply, we believe it’s a fantastic Foolish growth pick.What’s more, it deserves your attention today.So please don’t wait another moment. Simply click below to discover how you can take advantage of this. I have my eyes open for recovery stocks for 2021, and Indivior (LSE: INDV) has come storming into view. The FTSE 250 as a whole is sitting on a 6% loss over the past 12 months. But the Indivior share price has jumped by more than 250% in the same period.It’s still way down on a 2018 peak, with the shares going into tailspin in 2019. But what’s this new lease of life all about? And are we looking at long-term sustainable growth? The surge of the past few days is down to the company’s latest update.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Indivior is a pharmaceuticals company, specialising in opioid addiction treatment. The tragic opioid addiction crisis is big, especially in the USA. Sad though that is, any improvements in 2020’s profit outlook is good news for the firm. And that’s exactly what it delivered on 15 January. I could tell it was good just by looking at the Indivior share price, which jumped nearly 10% on the day.Indivior share price soaringMy Motley Fool colleague Manika Premsingh made a prediction: “I reckon that the latest news will provide continued impetus for INDV’s share price.” And how prescient that seems now. On Tuesday, it leads the FTSE 250 again, up another 9% at the time of writing. After a solid Monday too, the Indivior share price has now climbed 24% since the update was released.Indivior had previously indicated full-year revenue in the range of $595m to $620m. The results have easily exceeded that, with new expectations put at $645m to $650m. The company’s Sublocade product plays a big part in that, with net revenue now expected to come in between $128m and $130m (up from guidance of $120m to $125m). Other product revenue looks to be largely in line with guidance.On top of better-than-expected revenue, Indivior reported operating expenses slightly below guidance. Overall, the company “now expects to deliver adjusted pre-tax income ahead of its previous expectations.” Quite how far ahead we don’t yet know, so we’ll have to wait until full results are delivered on 18 February.Should I buy now?This all sounds good. But with the Indivior share price having more than trebled over the past year, would I buy now? Well, my portfolio might benefit from a growth stock or two. As far as future demand goes, I can’t see an end to the opioid crisis any time soon. Not when the majority of drugs-related deaths around the world are down to opioids.But I remain cautious for several reasons. One is that Indivior’s results have been a bit erratic. And I really like to see at least a slightly longer-term positive run before I buy a stock. The other is a £1bn claim brought against the company in November, by former parent Reckitt Benckiser. Indivior reckons the claim is baseless, but I’d rather wait and see. I might be missing some top growth profits by turning away from the Indivior share price right now. But I prefer to minimise risk these days, and there are many lower-risk investment candidates out there. Image source: Getty Images. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Our 6 ‘Best Buys Now’ Shares Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. FREE REPORT: Why this £5 stock could be set to surge I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. The Indivior share price is smashing the FTSE 250. Should I buy now? Alan Oscroft | Tuesday, 19th January, 2021 | More on: INDV See all posts by Alan Oscroft Get the full details on this £5 stock now – while your report is free.
Oxford academics have co-authored a review of fourteen recent studies which look into the link between internet usage and self-harm and suicide among young people.The review, which was published in October, has drawn attention to the worrying discovery that young people who contemplate harming or even killing themselves go online more often to find empathy from others in similar situations and pick up tips than to seek help to stop feeling suicidal. In some of the studies investigated, this was found to be true of well over half of the study’s participants.Professors Paul Montgomery and Keith Hawton, both academics based in Oxford, cited “growing concerns about the influence of the Internet on the risk of self-harm and suicide among young people” as their reason for embarking upon the project.They assembled as much of the current research literature as possible in order to see what information is already available. Professor Hawton said, “We were surprised that there were not more studies, given the theoretical importance of this issue… I am sure that more research is currently being conducted. One surprise was the contradictory nature of the research findings from different studies, with several indicating that the internet had had a positive, helpful impact (i.e. through social support and good advice).“However, the predominant theme was one of danger for distressed young people, especially in terms of gaining access to websites which seem to encourage suicidal behaviour.”The review found that the internet creates unfavourable conditions for young people thinking about suicide. It provides a cloak of anonymity which allows the vulnerable to remain hidden and the sinister troll to flourish. In a forum environment, violent thoughts can be normalised and take on a life of their own. Victimisation through cyber-bullying also loomed large in accounts of the influence of the internet upon desperate young minds.On what he hoped the impact of his research would be, Professor Hawton commented, “We hope more researchers will think about these issues and conduct further informative studies, and that clinicians will be encouraged to ask all distressed youngsters who come in as patients about their internet usage. Finally, we would like to see the development of internet sites that can provide support and therapy for young people who may be depressed and/ or suicidal.”Charlotte Hendy, a spokeswoman for OUSU’s Welfare division, had the following to say, “We empathise with anyone [enrolled at Oxford] who is thinking about self-harm, having negative thoughts or contemplating suicide, and would encourage them to seek help and support by contacting the University’s Counselling Service, Nightline or their GP.“Anyone wishing to get more involved in campaigning around the issues of mental health should join OUSU’s ‘Mind Your Head’ Campaign, which encourages people to think and talk about mental health and wellbeing.”
“The increase in the capital available for investments and intensifying competition affected the covenant policies adopted by fund managers,” it said.VER’s return on private credit funds dropped to 1.7% in 2019 from 12.4% the year before, while direct non-liquid lending produced a 4.9% return – up from 3.8% in 2018.The pension fund only has 2.1% of its overall portfolio invested in the category of “other fixed income investments”, which includes private credit funds and direct non-liquid lending.However, in general fixed income investments had performed better than expected.Timo Viherkenttä, VER’s chief executive officer, said: “The year was excellent, particularly for equity investments, but fixed income investments also proved a pleasant surprise, and VER invested quite heavily in the fixed income market in the emerging economies, which, once again, gave a splendid return.”Listed equities generated a 24.6% return, compared with -7.4% the year before, and liquid fixed income returned 5%, up from -1.9%, the pension fund reported.Central banks had played a key role during the year for market sentiment, VER said, with their assurances, action and continued expansive monetary policy serving to counteract uncertainties over the US-China trade talks and Brexit.The Financial Times yesterday reported that internationally, assets invested in private debt – largely made up of non-bank loans to unlisted companies – grew to a record $812bn (€732bn) last year, and that even industry insiders were warning “the boom in private debt is turning into a frenzy”.VER’s former leader Timo Löyttyniemi has rejoined the fund today as CEO after five years in a different job, replacing Viherkenttä who is now returning to academia. Finland’s State Pension Fund, Valtion Eläkerahasto (VER), has warned in its annual report that the increasing volume of capital now chasing private credit has affected covenant policies adopted by fund managers.The pension fund, which acts as a buffer for government staff pensions, posted a 13.8% return on investments for 2019 – up from 2018’s 3.4% loss. Listed real estate investment trusts (REITs) ending up as the most profitable asset class, producing a 28.1% return as the funds emulated the strong performance of the equity markets, VER said.Commenting on non-liquid fixed income investments, VER said in its annual report: “Non-existing or weaker loan collateral has given rise to concerns about future returns on private credit funds in the coming years.”The Helsinki-based fund said it had expected a correction in non-liquid fixed income markets for some time now, but that interest in private credit investments had continued to grow.
Tweet HealthInternationalLifestylePrint US to lift morning-after pill curbs by: – June 11, 2013 Share Sharing is caring! 39 Views no discussions Share Share The emergency contraceptive is effective if taken within 72 hours of unprotected sexThe US administration says it will no longer seek to block over-the-counter sales of emergency contraception to women and girls of all ages.This means that anyone will soon be able to buy the Plan B morning-after pill without a prescription.The justice department had fought against a federal judge’s order seeking to lift current age and sales limits.The move is seen as a breakthrough in the 12-year battle to make emergency contraception universally available.Under current laws, only girls aged 15 and older can purchase the morning-after pill without a prescription.However in April, US district judge Edward Korman ruled that the drug should be made available over-the-counter and without age restrictions.Plaintiffs in a federal lawsuit against the Food and Drug Administration (FDA) said the limit unfairly kept women and girls from accessing the drug, which is most effective when taken within 72 hours of intercourse.US government lawyers had appealed against Judge Korman’s ruling, arguing that he had exceeded his authority.But the justice department has now confirmed that the FDA will drop its appeal and prepare a plan to comply with the ruling.In 2011, the FDA concluded that the morning-after pill could be safely used by girls of child-bearing age and should be unrestricted.But US Health and Human Services Secretary Kathleen Sebelius over-ruled the agency, barring girls under 17 from buying the pills without a prescription.The FDA dropped this age limit to 15 in April this year.But Judge Korman called that rule “politically motivated, scientifically unjustified and contrary to agency precedent”.BBC News